210,914 Skin-Infection Cases in Active U.S. Military Personnel

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional activity or service setting. It is not a patient, diagnosis, before-and-after image, institutional endorsement or Dr. Arsy #003 treatment result.

Reader question: What did this specific study measure, in whom, at what timepoint—and which conclusions would go beyond its evidence?

Study snapshot

Study element	Reported detail
Population	Active-component U.S. military personnel under surveillance from 2016 through September 2020.
Design	Retrospective population surveillance using medical encounter and operational-theater records for skin and soft-tissue infections.
Comparator	Incidence was compared over time and across demographic and service subgroups.
Timepoint	January 2016 through September 2020.
Key result	Surveillance identified 210,914 incident cases, an overall rate of 352.8 per 10,000 person-years; 4,250 cases occurred in operational theaters. A total of 174,893 members received care across 307,160 encounters and 14,819 hospital bed-days. The rate declined 21.9% over the study period.
Funding/conflict context	The military surveillance report does not evaluate a skincare product; the accessible record does not report commercial product funding.

What was actually measured?

Surveillance identified 210,914 incident cases, an overall rate of 352.8 per 10,000 person-years; 4,250 cases occurred in operational theaters. A total of 174,893 members received care across 307,160 encounters and 14,819 hospital bed-days. The rate declined 21.9% over the study period.

The large denominator describes health-system burden, but administrative diagnosis codes are surveillance tools rather than microbiologic confirmation for every case.

The denominator defines the scope. A clinic series, outbreak investigation, surveillance database, questionnaire and prospective cohort answer different questions. Their percentages, rates and associations cannot be silently transferred to a different population, activity or setting.

What the result does not prove

Retrospective coding, changes in care-seeking and deployment, incomplete capture outside military care and an observational trend prevent assigning causes to the decline.

Observational timing and association do not automatically prove individual causation. Training load, footwear, shared surfaces, hygiene, climate, protective equipment, prior conditions, referral practices and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors’ conclusions, this interpretation or any product.

Condition categories should stay separate

Dryness, friction injury, dermatitis, fungal disease and bacterial infection are not interchangeable. A moisturizer may support hydration and the moisture barrier, but it does not diagnose an infection, replace medical evaluation or substitute for activity-specific prevention and infection-control measures.

For suspected infection, clinicians may need examination, microscopy, culture or other testing. Persistent spreading redness, drainage, fever, severe pain, rapidly worsening symptoms or major loss of function warrants prompt professional evaluation.

Activity details worth documenting

Which surface, footwear, glove, mat, pool, uniform, climate or training load came before the change?
Where did the problem begin, and did it change during rest, travel, deployment or a different facility?
Were skin, towels, clothing, equipment or showers shared, and how were surfaces cleaned?
How often were skin areas wet, occluded, rubbed, heated, chilled or exposed to sun?
Did the problem alter sleep, pace, attendance, training, competition or work safety?

Prevention comes before cosmetic care

Useful prevention is matched to the hazard: equipment and facility hygiene, prompt showering, clean personal textiles, well-fitted footwear, friction management, task-appropriate protective equipment, ultraviolet protection and timely clinical assessment. No single step prevents every diagnosis.

Do not share personal skin products during an outbreak and do not place workplace or environmental materials on skin to test a theory. Follow facility, occupational-health, sports-medicine and public-health instructions for contagious conditions.

Primary research and authoritative guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema or infection, relieves pain or itch, neutralizes environmental exposures, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace, military, sports or infection-control determination.

← Back to Doctor's Notes